Transplantation Technologies & Research

ISSN: 2161-0991

Open Access

Intravesicle Bacillus Calmette–Guérin (BCG) Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) in the Transplanted Patients Population: A Systematic Review of the World Literature


Omer A Raheem, Ehab A Eltahawy, Rodney Davis and Mohamed H. Kamel

Intravesicle Bacille Calmette-Guerin (BCG) is generally considered to be contraindicated in the immunosuppressed or compromised patients with bladder cancer (BC) because of ineffectiveness or partial toxicities. Therefore, there is little experience with BCG in individual with impaired immune system and this can be challenging to practicing urologists. We sought to review the current available evidence of utilizing intravesicle BCG for BC in patients with solid organ transplantation and commented on its current status.


Share this article

Google Scholar citation report
Citations: 223

Transplantation Technologies & Research received 223 citations as per Google Scholar report

Transplantation Technologies & Research peer review process verified at publons

Indexed In

arrow_upward arrow_upward